Jane Rhodes, Verge Genomics Chief Business Officer

Verge Ge­nomics teams up with As­traZeneca in drug dis­cov­ery deal

Verge Ge­nomics has se­cured its largest deal yet, link­ing up with As­traZeneca’s rare dis­ease di­vi­sion Alex­ion in a deal worth up to $882 mil­lion. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.